[概述]TREATMENT

Imatinib : Mesylate ( Gleevec ) 400-600 mg/d , To inhibit the combination of ATP with tyrosine kinase , 95%patients achieved hematologic CR .Allo-PBSCT , in 1st CP 5years survival 55%, in 2nd CP or AP , 25%. ......

——《Essential Internal Medicine》

书名：《Essential Internal Medicine》

栏目：Essential Internal Medicine > PART 6 HEMATOLOGICAL DISEASES > Chapter 4 Leukemia > CHRONIC MYELOGENOUS LEUKEMIA (CML)

作者：Joseph JY SUNG Ji-yao WANG T

参编：Guang，fengSHI，LawrenceKSWONG，Xiao，weiYAN，JulianaCNCHAN（陈重娥），FrancisKLCHAN（陈家亮）

页码：369

版本：1

出版社：人民卫生出版社

出版时间：2009-05-01

▲ [诊断]一、FAB分型诊断

▼ [概述]ETIOLOGY AND PATHOGENESIS

查看相关

[概述]ETIOLOGY AND PATHOGENESIS

[概述]TREATMENT

[概述]Chapter 2 Alcoholic and Non-alcoholic Fatty Liver Disease

[概述]Chapter 6 Inflammatory Bowel Disease

[专著速查][诊断]一、FAB分型诊断

[专著速查][概述]Chapter 8 Disorders of Aci

[专著速查][概述]CLINICAL FEATURES

[专著速查][辅助检查]四、aEEG在新生儿领域的

[专著速查][概述]INVESTIGATIONS